Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.
Sivan Schipper, Kabir Nigam, Yasmin Schmid...
https://pubmed.ncbi.nlm.nih.gov/39260823/Actively Recruiting
Led by University Hospital, Basel, Switzerland · Updated on 2026-04-29
60
Participants Needed
4
Research Sites
34 weeks
Total Duration
Researchers are evaluating the effects of lysergic acid diethylamide LSD on psychosocial distress in patients with advanced or end-stage fatal diseases who have a life expectancy between 12 weeks and 2 years. This phase II, randomized, double-blind, active placebo-controlled study aims to assess changes in depressive symptoms, anxiety, pain, quality of life, spiritual well-being, demoralization, and caregiver burden among 60 participants. Participants will be randomly assigned in a 21 ratio to one of two groups. The treatment group will receive two moderate to high oral doses of LSD 100 g followed by either 100 g or 200 g, while the control group will receive two low doses of LSD 25 g for both sessions as an active placebo. The study involves two dosing sessions with assessments at multiple time points. During the study, participants will complete various questionnaires and evaluations measuring anxiety state anxiety inventory, pain levels, opioid use, spiritual well-being, demoralization, quality of life, and other psychological and behavioral factors. Assessments occur before and after each intervention, including follow-ups up to 9 weeks after the second dose. Researchers will also monitor adverse events, vital signs during dosing sessions, and collect qualitative data through interviews. Total participation duration extends up to about 9 weeks after the last intervention.
CONDITIONS
Lysergic Acid Diethylamide (LSD) in Palliative Care
Y
Yasmin Schmid, PD Dr. med.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University Hospital, Basel, Switzerland
Lead Sponsor
University Hospital, Zürich
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 9 weeks after second intervention
Participants receive two sessions of oral lysergic acid diethylamide (LSD) at specified doses.
2 drug administration sessions with assessments before and up to 12 hours after each session, plus multiple follow-up visits up to 9 weeks after second intervention
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Sivan Schipper, Kabir Nigam, Yasmin Schmid...
https://pubmed.ncbi.nlm.nih.gov/39260823/University Hospital, Basel, Switzerland
Lead Sponsor
University Hospital, Zürich
Collaborating Sponsor